196 related articles for article (PubMed ID: 37787373)
41. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.
Little JS; Tandon M; Hong JS; Nadeem O; Sperling AS; Raje N; Munshi N; Frigault M; Barmettler S; Hammond SP
Blood Adv; 2023 Sep; 7(18):5485-5495. PubMed ID: 37486599
[TBL] [Abstract][Full Text] [Related]
42. New targets for CAR T therapy in hematologic malignancies.
Savani M; Oluwole O; Dholaria B
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
[TBL] [Abstract][Full Text] [Related]
43. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
Mercadal S; Gomez CA; Lee CJ; Couriel DR
Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975
[TBL] [Abstract][Full Text] [Related]
44. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
[TBL] [Abstract][Full Text] [Related]
45. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
46. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
Li H; Zhao L; Sun Z; Yao Y; Li L; Wang J; Hua T; Ji S; Wang S; Cheng H; Shi M; Li Z; Zeng L; Wu Q; Qiao J; Chen C; Zheng J; Cao J; Xu K
Front Immunol; 2022; 13():1019548. PubMed ID: 36330523
[TBL] [Abstract][Full Text] [Related]
47. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
48. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche JC
Semin Hematol; 2023 Jan; 60(1):52-58. PubMed ID: 37080711
[TBL] [Abstract][Full Text] [Related]
49. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
50. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Jain T; Knezevic A; Pennisi M; Chen Y; Ruiz JD; Purdon TJ; Devlin SM; Smith M; Shah GL; Halton E; Diamonte C; Scordo M; Sauter CS; Mead E; Santomasso BD; Palomba ML; Batlevi CW; Maloy MA; Giralt S; Smith E; Brentjens R; Park JH; Perales MA; Mailankody S
Blood Adv; 2020 Aug; 4(15):3776-3787. PubMed ID: 32780846
[TBL] [Abstract][Full Text] [Related]
51. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
52. Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up.
Cheng J; Huang J; Cao W; Huang L; Mao X; Chen L; Zhou J; Wang N
Front Immunol; 2023; 14():1226148. PubMed ID: 37849765
[TBL] [Abstract][Full Text] [Related]
53. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
54. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
55. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
57. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
58. Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
Xie D; Jin X; Sun R; Zhang M; Wang J; Xiong X; Zhang X; Zhao M
Technol Cancer Res Treat; 2022; 21():15330338221118413. PubMed ID: 35989682
[TBL] [Abstract][Full Text] [Related]
59. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
Schroeder BA; Jess J; Sankaran H; Shah NN
Curr Opin Hematol; 2022 Jul; 29(4):225-232. PubMed ID: 35787551
[TBL] [Abstract][Full Text] [Related]
60. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
